Even for a drug class accustomed to fast reviews, FDA granted an ultra-rapid accelerated approval to Bristol-Myers Squibb Co.’s Opdivo (nivolumab) with its May 17 clearance for Hodgkin lymphoma.
The approval was fast even by FDA’s recent expeditious standards for life-saving medicines that have been granted breakthrough therapy designation and accelerated reviews
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?